Renephra

Pioneering the treatment of
fluid overload and oedema

Management Team

Dr Idalia Dawidowska

Dr Idalia Dawidowska

CEO
LinkedIn | Email

Idalia has many years of international commercial experience within the pharmaceutical sector followed by several years of research commercialisation supporting university spin-out ventures. She is the founder and director of ID Venture Ltd which works with university incubators and academic founders to develop innovations and technologies into products and services with real commercial prospects. Previously she spent 10 years with AstraZeneca where she held various roles including Regional Marketing Manager for Central and Eastern Europe. Idalia also holds a degree in medicine and an MBA with merit from the Manchester Business School.

Alastair Taylor

Alastair Taylor

Chairman
LinkedIn | Email

Alistair is an experienced global business manager and chairman having spent decades in leadership positions in blue-chip medical device operations of >£100m value. For example, Alistair led the IPO, growth (to $1bn market cap) and exit of Biocompatibles International PLC, the world’s first coated coronary stent company. He is also a board member for OR Productivity.

Dr Leonard Ebah

Dr Leonard Ebah

Scientific Advisor
LinkedIn

Leonard is a Consultant Nephrologist and a Deputy Clinical Director for Directorate of Renal Medicine at Manchester Royal Infirmary. In 2012, he completed his PhD at the University of Manchester titled “Extraction and Analysis of Interstitial Fluid and Characterisation of the Interstitial Compartment in Kidney Disease” was recognised as outstanding and he won The Postgraduate Student of the Year Distinguished Awards Medal. For his interstitial fluid extraction work he gained further recognition by winning prizes such as the Young Innovator Award at the American Society of Artificial Internal Organs and the European Renal Association Fellowship award. Leonard leads ongoing research in the area of interstitial fluid extraction.

Duncan Keeble

Duncan Keeble

COO
LinkedIn

Duncan has worked in the medical devices industry for over 19 years, primarily leading the design and development of implantable medical devices. He has worked in startups and small companies in close partnership with multinational corporations, he has gained a deep understanding of the process of taking a medical device from concept to market. He has particular expertise in quality systems and design control for the EU, US and Japanese markets.

Professor Paul Brenchley

Professor Paul Brenchley

Founder and Director
LinkedIn

Paul is head of the renovascular biology research group in cardiovascular research. He directs the renal research labs and coordinates research for the Manchester Institute of Nephrology and Transplantation based at Manchester Royal Infirmary.

Dr Sandip Mitra

Dr Sandip Mitra

Founder and Director
LinkedIn

Sandip is a Consultant Nephrologist at Manchester Royal Infirmary where he leads the largest home haemodialysis programme in Europe. Sandip is an international key opinion leader and expert advisor to the scientific community and global industry leaders in dialysis at the National Horizons Scanning Centre and Department of Public Health. Sandip was recognised by HSJ as one of the top 50 UK Innovators in healthcare in November 2013.

Board of Directors

Dr Savvas Neophytou

Dr Savvas Neophytou

Investment Director
LinkedIn

Savvas is a Partner and Head of Life Sciences at funding specialists Deepbridge Capital. Prior to joining Deepbridge, Savvas enjoyed a 15 year career in the City, working as an investment banker at JP Morgan, Bear Stearns, Shore Capital, Cantor Fitzgerald, and Panmure Gordon. Savvas was also CEO of telemedicine business Now Healthcare Group. As a highly acclaimed analyst, Savvas has won multiple awards, most recently in 2015 when Savvas was ranked 2nd overall in the prestigious Reuters Starmine survey, a position he also held in 2014. In the same year, Savvas was also runner-up in the CityAM Analyst of the Year awards. Savvas holds a PhD in psychopharmacology from Nottingham University and a BSc (Hons) degree in pharmacology from Manchester University.

Dr Mark Rahn

Dr Mark Rahn

Investment Director
LinkedIn

Mark is an experienced Venture Capital Investment Manager and interim executive.

Since 2008, Mark has led the Manchester operation for the renowned UMIP Premier Fund, innovating in IP management, funding and incubation processes, including the highly successful proof of principle investment program at the University of Manchester. In addition, through investment and board directorship with both MTI and EV Group, Mark has played leading roles in the creation of a number of now well established high growth businesses bringing game changing electronic, environmental and health technologies to market.

As an interim executive and entrepreneur Mark has led business operations in the fields of advanced materials and medical devices, and for two years led the IP operation for The University of Manchester in the Nobel Prize winning field of graphene, arming it for successful exploitation and bringing it to a position of international IP leadership.

Prior to 2001, as a scientist, Mark has made important contributions to the fields of laser physics, optoelectronic materials and femtosecond spectroscopy.

Contact

T:  +44 161 667 1089

E:  info@renephra.com

Renephra Limited
MedTech Centre
Greenheys
Manchester Science Partnerships
Pencroft Way
M15 6JJ
Google Maps

map

© 2017  Renephra Ltd.  All rights reserved.